Cargando…
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
PURPOSE: Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of novel treatments, including immunotherapy. RATIONALE: Patient-derived T cells can be genetically modified to express chimeric antigen receptors (CARs) specific to tumor-associated antigens...
Autores principales: | Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438636/ https://www.ncbi.nlm.nih.gov/pubmed/25890361 http://dx.doi.org/10.1186/s12967-015-0460-x |
Ejemplares similares
-
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017) -
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
por: Mun, Sung Soo, et al.
Publicado: (2023) -
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020) -
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021) -
Primary osteosarcoma of the uterus with cardiac and pulmonary metastases
por: Abraham, Cynthia, et al.
Publicado: (2014)